Propranolol was effective in controlling the proliferative phase of problematic IH. It was well tolerated in our study. Outpatient treatment is possible if parents follow strict guidelines. Propranolol should be a first-line treatment for problematic IH in carefully selected patients.

We believe that laser-induced FFD is under-diagnosed as a newly reported adverse event of laser hair removal. It is clinically and histopathologically similar to classic FFD.

Background: Propranolol, a nonselective b-blocker, has been reported as efficient for controlling the growth of complicated infantile hemangiomas (IHs). No uniformly accepted protocol exists regarding the administration of oral propranolol for IH.Objective: We sought to share our experience using propranolol for problematic IH and to evaluate the efficacy of this treatment modality.Methods: A retrospective chart review analysis was performed for 35 consecutive children treated with propranolol as an oral solution on an outpatient basis in our dermatology/vascular anomalies clinic. A protocol was established with the help of our pediatric cardiologists, including pretreatment electrocardiography and echocardiography. Medical photographs taken after 2 months of treatment were rated by two independent evaluators.Results: We treated 31 girls and 4 boys with a median age of 3.5 months. Rapid improvement was reported in the first days of treatment in 34 patients. Mean improvement after 2 months was 61.5%. No serious adverse effects were reported.Conclusion: Propranolol was effective in controlling the proliferative phase of problematic IH. It was well tolerated in our study.Outpatient treatment is possible if parents follow strict guidelines. Propranolol should be a first-line treatment for problematic IH in carefully selected patients.Renseignements de base: Le propranolol, un bê ta-bloquant non sé lectif, s'est ré vé lé efficace pour maîtriser la croissance des hé mangiomes infantiles compliqué s. On ne dispose pas d'un protocole uniformé ment accepté quant à l'administration du propranolol oral contre l'hé mangiome infantile.Objectif: Nous voulions faire part de notre expé rience d'utilisation du propranolol pour traiter les hé mangiomes infantiles problé matiques et é valuer l'efficacité de cette modalité de traitement.Mé thodes: On a exé cuté une analyse ré trospective des dossiers de 35 enfants consé cutifs qui ont é té traité s par une solution orale de propranolol de faç on ambulatoire dans notre clinique de dermatologie/d'anomalies vasculaires. On a é tabli un protocole avec l'aide de nos cardiologues pé diatriques, lequel comprenait notamment un ECG et une é chographie cardiaque avant le traitement. Les photographies mé dicales prises aprè s 2 mois de traitement ont é té é valué es par deux é valuateurs indé pendants.Ré sultats: Nous avons traité 31 filles et 4 garç ons dont l'â ge mé dian é tait de 3,5 mois. On a signalé , chez 34 patients, une amé lioration rapide dè s les premiers jours de traitement. L'amé lioration moyenne aprè s deux mois s'é levait à 61,5 %. Aucun effet indé sirable grave n'a é té signalé .Conclusion: Le propranolol é tait efficace pour maîtriser la phase prolifé rative de l'hé mangiome infantile problé matique. Lors de notre é tude, il a é té bien tolé ré . Le traitement peut ê tre administré de faç on ambulatoire si les parents observent les directives à la lettre. Nous croyons qu'en pré sence d'un hé mangiome infantile problé matique, le traitement par le propranolol doit ê tre admi...